Assessing Canine Parvovirus Vaccine Performance in Puppies with Maternally Derived Antibody: An Improved Study Design
Abstract
1. Introduction
2. Materials and Methods
2.1. Animals and Housing
2.2. Ethics Statement
2.3. Vaccines
2.4. Blood Sampling and Serology
2.5. Virus Isolation from Rectal Swabs
2.6. Study Design
Group (Vaccine) | Vaccinate/Sentinel | Pup ID | Pup Sex | Mean HAI Titre Day 0 |
---|---|---|---|---|
1 (Nobivac DP PLUS) | V1 | 8638 | M | 523 |
S1 | 9012 | F | 469 | |
V2 | 8668 | F | 427 | |
S2 | 8644 | F | 427 | |
V3 | 9040 | M | 427 | |
S3 | 2681 | F | 117 | |
V4 | 8662 | F | 131 | |
S4 | 8654 | M | 93 | |
V5 | 8728 | M | 72 | |
S5 | 8648 | M | 47 | |
2 (Vanguard Plus 5) | V1 | 1848 | F | 213 |
S1 | 1990 | M | 120 | |
V2 | 9426 | M | 187 | |
S2 | 2318 | F | 93 | |
V3 | 9425 | M | 173 | |
S3 | 1988 | M | 87 | |
V4 | 1849 | F | 72 | |
S4 | 9429 | F | 60 | |
3 (Versican Plus P) | V1 | 4602 | M | 480 |
S1 | 4541 | M | 288 | |
V2 | 4603 | F | 395 | |
S2 | 4596 | M | 131 | |
V3 | 4546 | F | 288 | |
S3 | 4542 | M | 288 | |
V4 | 4545 | M | 131 | |
S4 | 4599 | M | 131 | |
4 (Eurican Primo P) | V1 | 4601 | F | 480 |
S1 | 4597 | M | 261 | |
V2 | 4547 | M | 373 | |
S2 | 4595 | M | 261 | |
V3 | 4544 | F | 261 | |
S3 | 4548 | F | 131 | |
V4 | 4543 | M | 131 | |
S4 | 4598 | M | 104 |
2.7. Statistical Analysis
3. Results
Group (Vaccine) | Pup ID | V/S * | Study Day | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 3 | 5 | 7 | 9 | 11 | 14 | 18 | 21 | 25 | 28 | |||
1 (Nobivac DP PLUS) | 8638 | V1 | 523 | 373 | 213 | 65 | 9216 | 11,947 | 23,893 | 23,211 | 20,480 | 11,947 | 11,947 |
9012 | S1 | 469 | 331 | 235 | 165 | 165 | 144 | 144 | 117 | 144 | 107 | 96 | |
8668 | V2 | 427 | 373 | 187 | 87 | 800 | 7680 | 13,312 | 11,947 | 12,629 | 16,725 | 15,360 | |
8644 | S2 | 427 | 373 | 288 | 235 | 240 | 165 | 17 | 13,653 | 25,259 | 20,139 | 9728 | |
9040 | V3 | 427 | 334 | 288 | 144 | 144 | 13,392 | >40,960 | >40,960 | >81,920 | 45,056 | >40,960 | |
2681 | S3 | 117 | 93 | 65 | 36 | 41 | <16 | 96 | 9899 | 10,923 | 6997 | 4437 | |
8662 | V4 | 131 | 83 | 36 | 939 | 9899 | 7253 | 16,725 | 18,432 | 12,629 | 17,067 | 9728 | |
8654 | S4 | 93 | 53 | 53 | 47 | 36 | 72 | 8363 | 21,845 | 20,480 | 13,995 | 9728 | |
8728 | V5 | 72 | 72 | 29 | 1600 | 11,947 | 11,947 | 20,651 | 18,432 | 13,995 | 17,067 | 10,581 | |
8648 | S5 | 47 | 36 | 36 | 33 | <16 | 3456 | 16,725 | 18,432 | 17,067 | 9216 | 7509 | |
2 (Vanguard Plus 5) | 1848 | V1 | 213 | 144 | 144 | 131 | 93 | 144 | 117 | 65 | 41 | 36 | 30 |
1990 | S1 | 120 | 93 | 93 | 72 | 59 | 65 | 59 | 36 | 30 | 27 | 18 | |
9426 | V2 | 187 | 131 | 133 | 107 | 131 | 261 | 144 | 72 | 59 | 41 | 36 | |
2318 | S2 | 93 | 65 | 72 | 47 | 36 | 36 | 36 | 27 | 23 | 24 | <16 | |
9425 | V3 | 173 | 93 | 107 | 240 | 1877 | 2987 | 1877 | 1152 | 939 | 661 | 661 | |
1988 | S3 | 87 | 72 | 72 | 53 | 36 | 33 | 36 | 27 | 23 | 21 | 17 | |
1849 | V4 | 72 | 59 | 72 | 288 | 939 | 4608 | 3755 | 2645 | 2091 | 1877 | 2219 | |
9429 | S4 | 60 | 53 | 41 | 29 | 30 | 33 | 24 | 18 | 18 | 18 | <16 | |
3 (Versican Plus P) | 4602 | V1 | 480 | 240 | 192 | 165 | 165 | 179 | 165 | 107 | 120 | 60 | 53 |
4541 | S1 | 288 | 165 | 144 | 165 | 131 | 131 | 107 | 85 | 79 | 53 | 53 | |
4603 | V2 | 395 | 213 | 192 | 141 | 152 | 120 | 96 | 83 | 60 | 48 | 45 | |
4596 | S2 | 131 | 83 | 72 | 77 | 65 | 53 | 53 | 36 | 30 | 18 | 21 | |
4546 | V3 | 288 | 240 | 240 | 219 | 72 | 480 | 12,288 | 13,312 | 9216 | 7509 | 8533 | |
4542 | S3 | 288 | 240 | 240 | 165 | 187 | 131 | 165 | 96 | 107 | 60 | 53 | |
4545 | V4 | 131 | 83 | 83 | 83 | 288 | 9045 | 33,451 | 33,451 | 27,989 | 21,163 | 18,432 | |
4599 | S4 | 131 | 65 | 59 | 53 | 60 | 47 | 60 | 33 | 30 | 18 | 19 | |
4 (Eurican Primo P) | 4601 | V1 | 480 | 240 | 229 | 200 | 219 | 152 | 131 | 107 | 107 | 65 | 60 |
4597 | S1 | 261 | 131 | 120 | 107 | 120 | 76 | 83 | 52 | 41 | 33 | 35 | |
4547 | V2 | 373 | 240 | 261 | 131 | 192 | 131 | 131 | 101 | 83 | 65 | 60 | |
4595 | S2 | 261 | 131 | 131 | 107 | 120 | 107 | 83 | 65 | 60 | 33 | 41 | |
4544 | V3 | 261 | 187 | 165 | 144 | 131 | 120 | 747 | 3072 | 2645 | 1493 | 1152 | |
4548 | S3 | 131 | 76 | 83 | 60 | 53 | 47 | 48 | 33 | 30 | 18 | 17 | |
4543 | V4 | 131 | 76 | 72 | 65 | 72 | 853 | 13,653 | 9728 | 6827 | 4181 | 4181 | |
4598 | S4 | 104 | 60 | 53 | 67 | 38 | 30 | 48 | 33 | 30 | 18 | 18 |
Parameter | Group Comparison | ||
---|---|---|---|
1 vs. 2 | 1 vs. 3 | 1 vs. 4 | |
p-Value, LS Mean (95% CI) * | p-Value, LS Mean (95% CI) * | p-Value, LS Mean (95% CI) * | |
Mean CPV titres (log 2 converted): all pups | <0.0001, 3.59 (2.24, 4.95) | 0.0001, 2.65 (1.29, 4.00) | <0.0001, 3.15 (1.80, 4.50) |
Mean CPV titres (log 2 converted): excluding sentinel pups | 0.0112, 3.52 (0.95, 6.09) | 0.0453, 2.63 (0.06, 5.20) | 0.0164, 3.28 (0.70, 5.85) |
Group (Vaccine) | Pup ID | Vaccinate/Sentinel | Days on Which Virus Shed |
---|---|---|---|
1 (Nobivac DP PLUS) | 8638 | V1 | 6, 7, 8, 9 |
9012 | S1 | nd | |
8668 | V2 | 8, 9, 10 | |
8644 | S2 | 11, 15, 16, 17 | |
9040 | V3 | 9, 10, 11 | |
2681 | S3 | 13, 14, 15 | |
8662 | V4 | 6, 7 | |
8654 | S4 | 11, 12, 13, 14 | |
8728 | V5 | 6, 7 | |
8648 | S5 | 6, 10, 11, 12 | |
2 (Vanguard Plus 5) | 1848 | V1 | nd |
1990 | S1 | nd | |
9426 | V2 | nd | |
2318 | S2 | nd | |
9425 | V3 | nd | |
1988 | S3 | nd | |
1849 | V4 | nd | |
9429 | S4 | nd | |
3 (Versican Plus P) | 4602 | V1 | nd |
4541 | S1 | nd | |
4603 | V2 | nd | |
4596 | S2 | nd | |
4546 | V3 | 9, 10 | |
4542 | S3 | nd | |
4545 | V4 | 7, 8, 9, 10 | |
4599 | S4 | nd | |
4 (Eurican Primo P) | 4601 | V1 | nd |
4597 | S1 | nd | |
4547 | V2 | nd | |
4595 | S2 | nd | |
4544 | V3 | nd | |
4548 | S3 | nd | |
4543 | V4 | 10, 11 | |
4598 | S4 | nd |
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Niewiesk, S. Maternal antibodies: Clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front. Immunol. 2014, 5, 446. [Google Scholar] [CrossRef]
- Chastant-Maillard, S.; Freyburger, L.; Marcheteau, E.; Thoumire, S.; Ravier, J.F.; Reynaud, K. Timing of the intestinal barrier closure in puppies. Reprod. Domest. Anim. 2012, 47, 190–193. [Google Scholar] [CrossRef] [PubMed]
- Mila, H.; Grellet, A.; Desario, C.; Feugier, A.; Decaro, A.; Buoavoglia, C.; Chastant-Maillard, S. Protection against canine parvovirus type 2 infection in puppies by colostrum-derived antibodies. J. Nutr. Sci. 2014, 3, e54. [Google Scholar] [CrossRef] [PubMed]
- Chastant, S.; Mila, H. Passive immune transfer in puppies. Anim. Reprod. Sci. 2019, 207, 162–170. [Google Scholar] [CrossRef]
- Sykes, J.E. Sykes, J.E., Ed.; Immunization. In Greene’s Infectious Diseases of the Dog and Cat, 5th ed.; Elsevier: St. Louis, MO, USA, 2023; pp. 238–255. [Google Scholar]
- Squires, R.A.; Crawford, C.; Marcondes, M.; Whitley, N. 2024 guidelines for the vaccination of dogs and cats—Compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). J. Small Anim. Pract. 2024, 65, 277–316. [Google Scholar] [CrossRef]
- Baker, J.A.; Robson, D.S.; Gillespie, J.H.; Burgher, J.A.; Doughty, M.F. A nomograph that predicts the age to vaccinate puppies against distemper. Cornell Vet. 1959, 49, 158–167. [Google Scholar]
- Carmichael, L.E.; Robson, D.S.; Barnes, F.D. Transfer and decline of maternal infectious canine hepatitis antibody in puppies. Proc. Soc. Exp. Biol. Med. 1962, 109, 677–681. [Google Scholar] [CrossRef] [PubMed]
- Pollock, R.V.H.; Carmichael, L.E. Maternally Derived Immunity to Canine Parvovirus Infection: Transfer, Decline, and Interference with Vaccination. J. Am. Vet. Med. Assoc. 1982, 80, 37–42. [Google Scholar] [CrossRef]
- Buonavoglia, C.; Tollis, M.; Buonavoglia, D.; Puccini, A. Response of pups with maternal derived antibody to modified-live canine parvovirus vaccine. Comp. Immunol. Microbiol. Infect. Dis. 1992, 15, 281–283. [Google Scholar] [CrossRef]
- Chappuis, G. Control of canine distemper. Vet. Microbiol. 1995, 44, 351–358. [Google Scholar] [CrossRef]
- Parrish, C.R.; Sykes, J.E. Sykes, J.E., Ed.; Canine Parvovirus Infections and Other Viral Enteritides. In Greene’s Infectious Diseases of the Dog and Cat, 5th ed.; Elsevier: St. Louis, MO, USA, 2023; pp. 341–351. [Google Scholar]
- Meunier, P.C.; Cooper, B.J.; Appel, M.J.G.; Slauson, D.O. Pathogenesis of canine parvovirus enteritis: The importance of viremia. Vet. Pathol. 1985, 22, 60–71. [Google Scholar] [CrossRef]
- Ellis, J.; Marziani, E.; Aziz, C.; Brown, C.M.; Cohn, L.A.; Lea, C.; Moore, G.E.; Taneja, N. 2022 AAHA Canine Vaccination Guidelines (2024 Update). J. Am. Anim. Hosp. Assoc. 2024, 60, 1–19. [Google Scholar] [CrossRef]
- Decaro, N.; Buonavoglia, C.; Barrs, V.R. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication? Vet. Microbiol. 2020, 247, 108760. [Google Scholar] [CrossRef]
- Churchill, A.E. Preliminary development of a live attenuated canine parvovirus vaccine from an isolate of British origin. Vet. Rec. 1987, 120, 334–339. [Google Scholar] [CrossRef] [PubMed]
- Burtonboy, S.; Charlier, P.; Hertoghs, J.; Lobmann, M.; Wiseman, A.; Woods, S. Performance of high titre attenuated canine parvovirus vaccine in pups with maternally derived antibody. Vet. Rec. 1991, 128, 377–381. [Google Scholar] [CrossRef] [PubMed]
- de Cramer, K.G.M.; Stylianides, E.; van Vuuren, M. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus. Vet. Microbiol. 2011, 149, 126–132. [Google Scholar] [CrossRef]
- Wilson, S.; Siedek, E.; Thomas, A.; King, V.; Stirling, C.; Plevovád, E.; Salt, J.; Sture, G. Influence of maternally-derived antibodies in 6-week old dogs for the efficacy of a new vaccine to protect dogs against virulent challenge with canine distemper virus, adenovirus or parvovirus. Trials Vaccinol. 2014, 3, 107–113. [Google Scholar] [CrossRef]
- Pearce, J.; Spibey, N.; Sutton, D.; Tarpey, I. Development of a novel canine parvovirus vaccine capable of stimulating protective immunity in four-week-old puppies in the face of high levels of maternal antibodies. Vaccines 2023, 11, 1499. [Google Scholar] [CrossRef]
- Decaro, N.; Crescenzo, G.; Desario, C.; Cavalli, A.; Losurdo, M.; Colaianni, M.L.; Ventrella, G.; Rizzi, S.; Aulicino, S.; Lucente, M.S.; et al. Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination. Vaccine 2014, 32, 3850–3853. [Google Scholar] [CrossRef]
- Decaro, N.; Buonavoglia, C. Canine parvovirus post-vaccination shedding: Interference with diagnostic assays and correlation with host immune status. Vet. J. 2017, 221, 23–24. [Google Scholar] [CrossRef] [PubMed]
- Freisl, M.; Speck, S.; Truyen, U.; Reese, S.; Proksch, A.-L.; Hartmann, K. Faecal shedding of canine parvovirus after modified-live vaccination in healthy adult dogs. Vet. J. 2017, 219, 15–21. [Google Scholar] [CrossRef]
- Spibey, N.; Greenwood, N.M.; Sutton, D.; Chalmers, W.S.; Tarpey, I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet. Microbiol. 2008, 128, 48–55. [Google Scholar] [CrossRef]
- Churchill, A.E. Vaccination against canine parvovirus disease. Vet. Rec. 1982, 110, 344. [Google Scholar] [CrossRef] [PubMed]
- Mochizuki, M.; Harasawa, R.; Nakatani, H. Antigenic and genomic variabilities among recently prevalent parvoviruses of canine and feline origin in Japan. Vet. Microbiol. 1993, 38, 1–10. [Google Scholar] [CrossRef]
- Parrish, C.R.; Carmichael, L.E.; Antczak, D.F. Antigenic relationships between canine parvovirus type 2, feline panleukopenia virus and mink enteritis virus using conventional antisera and monoclonal antibodies. Arch. Virol. 1982, 72, 267–278. [Google Scholar] [CrossRef]
- European Medicines Agency. Reflection paper on the Demonstration of a Possible Impact of Maternally Derived Antibodies on Vaccine Efficacy in Young Animals. 2010. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-demonstration-possible-impact-maternally-derived-antibodies-vaccine-efficacy-young-animals_en.pdf (accessed on 27 March 2025).
- Carmichael, L.E.; Pollock, R.V.; Joubert, J.C. Response of puppies to canine-origin parvovirus vaccines. Modern Veterinary Practice 1984, 65, 99–102. [Google Scholar]
- Bazin, H. A brief history of the prevention of infectious diseases by immunisations. Comp. Immunol. Microbiol. Infect. Dis. 2003, 26, 293–308. [Google Scholar] [CrossRef] [PubMed]
Vaccine | Company | Antigens and Titres (TCID50) per Dose * |
---|---|---|
Nobivac DP PLUS | MSD Animal Health | CPV strain 630a 105.1 to 106.7 |
CDV strain Onderstepoort 105.1 to 106.5 | ||
Vanguard Plus 5 | Zoetis | CPV strain NL-35-D ≥ 107.0 |
CDV strain N-CDV ≥ 103.0 | ||
CAV strain Manhattan ≥ 103.2 | ||
CPi strain NL-CPI-5 ≥ 106.0 | ||
Versican Plus P | Zoetis | CPV strain Bio 12/B 104.3 to 106.6 |
Eurican Primo P | Boehringer Ingelheim | CPV strain 115-780916 ≥ 105.5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pearce, J.; Versmissen, E.; Sutton, D.; Cao, Q.; Tarpey, I. Assessing Canine Parvovirus Vaccine Performance in Puppies with Maternally Derived Antibody: An Improved Study Design. Vaccines 2025, 13, 832. https://doi.org/10.3390/vaccines13080832
Pearce J, Versmissen E, Sutton D, Cao Q, Tarpey I. Assessing Canine Parvovirus Vaccine Performance in Puppies with Maternally Derived Antibody: An Improved Study Design. Vaccines. 2025; 13(8):832. https://doi.org/10.3390/vaccines13080832
Chicago/Turabian StylePearce, Jacqueline, Ellen Versmissen, David Sutton, Qi Cao, and Ian Tarpey. 2025. "Assessing Canine Parvovirus Vaccine Performance in Puppies with Maternally Derived Antibody: An Improved Study Design" Vaccines 13, no. 8: 832. https://doi.org/10.3390/vaccines13080832
APA StylePearce, J., Versmissen, E., Sutton, D., Cao, Q., & Tarpey, I. (2025). Assessing Canine Parvovirus Vaccine Performance in Puppies with Maternally Derived Antibody: An Improved Study Design. Vaccines, 13(8), 832. https://doi.org/10.3390/vaccines13080832